A phase III trial with a multipeptide vaccine against tyrosinase, gp100 antigen, and MART-1 antigen in patients with resected melanoma showed that this vaccine was ineffective either alone or in combination with immunomodulatory molecule like GM-CSF in preventing recurrence of disease [68]. Here, PMEL is linked to melanoma.